Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.

Mochi Health, one of those implicated, is one of the largest telehealth providers of compounded GLP-1RAs. Eli Lilly maintains ...

Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the ...

Eli Lilly escalates its crackdown on unauthorized tirzepatide copies, filing lawsuits against four compounders accused of ...

that CagriSema failed to show better data than Eli Lilly’s tirzepatide, giving Eli Lilly the upper hand in the obesity market in the following years. Two weeks ago, Eli Lilly further extended ...

Eli Lilly recently experienced a slight decline ... and research findings supporting its diabetes therapy tirzepatide. Despite these positive announcements and steady performance data, the broader ...

Eli Lilly has filed a lawsuit against four telehealth platforms selling compounded versions of its blockbuster metabolic disorder drug tirzepatide, marking the latest power struggle between weight ...

Now, the tirzepatide shortage is over and deadlines for producing new copies of tirzepatide have passed, Eli Lilly is ...

Eli Lilly (NYSE:LLY) has filed lawsuits against four telehealth platforms that the pharma giant alleges are selling compounded versions of its blockbuster GLP-1/GIP receptor agonist tirzepatide ...